Trav13n-1 inhibitors are a class of chemical compounds that specifically interact with and inhibit the activity of the Trav13n-1 protein or receptor. These inhibitors function primarily by binding to the active site of the Trav13n-1 protein, effectively blocking the natural substrate or ligand from accessing the site, thereby preventing the protein from performing its normal biological role. In some instances, Trav13n-1 inhibitors may also act by binding to allosteric sites, which are locations on the protein separate from the active site. Binding to these allosteric sites induces conformational changes that modify the protein's structure and reduce its activity. The interactions between Trav13n-1 inhibitors and their target protein are stabilized by non-covalent forces, including hydrogen bonds, van der Waals interactions, electrostatic forces, and hydrophobic contacts. These interactions are crucial for ensuring that the inhibitor fits snugly within the protein's binding pocket and remains stable enough to prevent normal protein function.
The structural diversity of Trav13n-1 inhibitors is a key aspect of their design, with these compounds ranging from small organic molecules to more complex chemical entities. Common structural features of these inhibitors include aromatic rings, heterocycles, and functional groups like hydroxyl, carboxyl, or amine groups, which enhance their ability to form specific and stable interactions with the Trav13n-1 protein. The physicochemical properties of these inhibitors, such as molecular weight, polarity, and solubility, are carefully optimized to ensure high binding affinity and selectivity for Trav13n-1. For example, hydrophobic regions within the inhibitor are often designed to interact with non-polar areas of the Trav13n-1 protein, while polar or charged groups enable interactions with polar residues. This balance of hydrophobic and hydrophilic interactions ensures that Trav13n-1 inhibitors can modulate the protein's activity effectively, while maintaining the necessary stability and solubility under various biological conditions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which can inhibit Trav13n-1 by preventing its phosphorylation and subsequent activation, as the protein's function is dependent on its phosphorylation state. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, which is a kinase that could be upstream of Trav13n-1, leading to its activation. Inhibition of PI3K would, therefore, result in reduced Trav13n-1 activity due to lack of activating signals. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 specifically inhibits MEK, which is involved in the MAPK/ERK pathway. If Trav13n-1 activity is regulated by the MAPK/ERK pathway, inhibition of MEK would result in decreased activation of Trav13n-1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, and if Trav13n-1 is activated by JNK signaling, inhibiting JNK would decrease Trav13n-1 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. If Trav13n-1 is regulated through the p38 MAPK pathway, inhibition of p38 MAPK would lead to a decrease in Trav13n-1 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, which could reduce Trav13n-1 activity by preventing activation signals that are mediated through the PI3K pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are integral components of the MAPK/ERK pathway. By inhibiting these kinases, U0126 would prevent the activation of downstream proteins such as Trav13n-1, assuming it is regulated by this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which may be involved in the activation of Trav13n-1 as part of the PI3K/AKT/mTOR pathway. Inhibition of mTOR would result in decreased Trav13n-1 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family kinase inhibitor. If Trav13n-1 is activated by Src family kinases, inhibition by PP2 would decrease Trav13n-1 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Bcr-Abl kinase and Src family kinase inhibitor. If Trav13n-1 functions downstream of these kinases, inhibition by Dasatinib would lead to decreased Trav13n-1 activity. | ||||||